XM无法为美国居民提供服务。

XM无法为美国居民提供服务。
A
A

Abbott

市场新闻

Reuters - 45分钟前

Jury urged to hold formula makers responsible for premature baby's illness

UPDATE 1-Jury urged to hold formula makers responsible for premature baby's illness Adds material from Abbott, Mead Johnson opening statements By Brendan Pierson Oct 2 (Reuters) - A lawyer for a Missouri mother on Wednesday urged jurors to hold Abbott ABT.N , Reckitt's RKT.L Mead Johnson unit and St. Louis Children's Hospital responsible for a severe intestinal illness that she says her prematurely born son developed after the hospital fed him the companies' formulas.
A
Reuters - 3小时前

Jury urged to hold formula makers responsible for premature baby's illness

Jury urged to hold formula makers responsible for premature baby's illness By Brendan Pierson Oct 2 (Reuters) - A lawyer for a Missouri mother on Wednesday urged jurors to hold Abbott ABT.N , Reckitt's RKT.L Mead Johnson unit and St. Louis Children's Hospital responsible for a severe intestinal illness that she says her prematurely born son developed after the hospital fed him the companies' formulas.
A
Reuters - 1天前

U.S. STOCKS Dine Brands, Pinterest, Nike

BUZZ-U.S. STOCKS ON THE MOVE-Dine Brands, Pinterest, Nike Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes took a beating on Tuesday as reports of escalating tensions in the Middle East made investors sell riskier assets, with the benchmark S&P 500 hitting its lowest in over a week.
A
A
C
L
N
P
S
L
U
U
L
A
C
J
M
Reuters - 1天前

Uptake of Dexcom's OTC glucose monitor Stelo outpaces Abbott's Lingo, Citi says

BUZZ-Uptake of Dexcom's OTC glucose monitor Stelo outpaces Abbott's Lingo, Citi says ** Brokerage Citi says early uptake of Dexcom's DXCM.O over-the-counter continuous glucose monitor Stelo is ahead of Abbott's ABT.N Lingo ** Stelo is gaining traction benefitting from an earlier launch compared to Lingo - Citi ** Adds app data points to a recovery for Dexcom, after the glucose monitor maker slashed its annual revenue forecast ** Brokerage says downloads of apps for Dexcom's continuous glucose mo
A
Reuters - 2天前

UK's Reckitt falls after court trial over premature baby formula begins

BUZZ-UK's Reckitt falls after court trial over premature baby formula begins ** Shares of Enfamil formula maker Reckitt RKT.L down 1.15% at 4,524p ** Co's unit Mead Johnson, along with US-based Abbott ABT.N , is facing a trial over its premature baby formula causing a severe intestinal illness ** Plaintiffs argue companies failed to warn about the
A
Reuters - 2天前

UK Stocks-Factors to watch on Oct 1

UPDATE 1-UK Stocks-Factors to watch on Oct 1 Adds new items, updates futures Oct 1 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher, with futures FFIc1 up 0 .4%. * HALEON: Pfizer PFE.N offloaded shares worth roughly $3.26 billion in Haleon HLN.L at 380 pence apiece, cutting its stake to 15% in the world's largest standalone consumer healthcare firm, a bookrunner said.
A
G
P
R
Reuters - 2天前

UK Stocks-Factors to watch on Oct 1

UK Stocks-Factors to watch on Oct 1 Oct 1 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher, with futures FFIc1 up 0.34% * HALEON: Pfizer's PFE.N stake sale in British consumer healthcare company Haleon HLN.L has been upsized by 100 million shares to 640 million shares worth about $3.25 billion with strong demand from investors, a bookrunner familiar with the offering said on Monday.
A
P
Reuters - 2天前

Abbott, Reckitt face trial over premature baby formula amid alarm from doctors

CORRECTED-Abbott, Reckitt face trial over premature baby formula amid alarm from doctors Corrects title of Jonathan Davis in paragraph 9, to Chief of Newborn Medicine at Tufts Medical Center Doctors fear losing access to essential formulas for premature babies Plaintiffs argue companies failed to warn about NEC risk from cow's milk-based formula By Brendan Pierson Sept 30 (Reuters) - A Missouri mother and her lawyers this week will aim to convince a jury that Abbott ABT.N , Reckitt's RKT.L Mead
A
Reuters - 2周前

Indian shares set to open higher on US rate-cut euphoria

INDIA STOCKS-Indian shares set to open higher on US rate-cut euphoria BENGALURU, Sept 20 (Reuters) - Indian shares are set to open higher on Friday, as an outsized interest rate reduction by the U.S. Federal Reserve and the anticipation of a soft landing for the world's largest economy boosted risk appetite across global markets. The GIFT Nifty GIFc1 was at 25,523 points, as of 07:55 a.m.
A
U
Reuters - 2周前

U.S. STOCKS Children's Place, US energy sector, retailers

BUZZ-U.S. STOCKS ON THE MOVE-Children's Place, US energy sector, retailers Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes soared on Thursday with the S&P 500 and the Dow hitting intraday record highs after the Federal Reserve kicked off its monetary easing cycle with half-a-percentage point reduction and forecast more interest rate cuts were on the hor
A
A
C
C
I
J
L
M
N
T
A
U
F
R
U
U
S
D
Reuters - 2周前

Abbott Declares Qtrly Common Dividend Of 55 Cents/Shr

BRIEF-Abbott Declares Qtrly Common Dividend Of 55 Cents/Shr Sept 19 (Reuters) - Abbott Laboratories ABT.N : ABBOTT - DECLARED A QUARTERLY COMMON DIVIDEND OF 55 CENTS PER SHARE ABBOTT DECLARES 403RD CONSECUTIVE QUARTERLY DIVIDEND Source text for Eikon: ID:nPnbB2dYca Further company coverage: ABT.N
A
Reuters - 2周前

Piper Sandler initiates coverage on Abbott with 'overweight' rating

BUZZ-Piper Sandler initiates coverage on Abbott with 'overweight' rating ** Brokerage Piper Sandler initiates coverage on Abbott Laboratories ABT.N with overweight rating and PT of $131 ** Says while execution has been strong, ABT shares have underperformed YTD due to the ongoing litigation related to necrotizing enterocolitis (NEC) in premature babies, which has been an overhang ** Brokerage believes the potential damages related to the lawsuit are already priced in ** Considers ABT to be "one
A
Reuters - 2周前

U.S. Athira Pharma, Lowe's Companies, P&G

U.S. RESEARCH ROUNDUP-Athira Pharma, Lowe's Companies, P&G Sept 19 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Athira Pharma, Lowe's Companies and P&G on Thursday. HIGHLIGHTS * Athira Pharma Inc ATHA.O : Mizuho cuts to neutral from outperform * Five Below Inc FIVE.O : JP Morgan cuts to underweight from neutral * Lowe's Companies Inc LOW.N : TD Cowen raises target price to $265 from $240 * P&G PG.N : JP Morgan rai
A
A
C
D
M
N
T
A
C
Reuters - 2周前

India's pharma index climbs after bumper Fed rate cut

BUZZ-India's pharma index climbs after bumper Fed rate cut ** India's Nifty pharma index .NIPHARM climbs 0.5%, snapping three straight sessions of losses ** Rise after the U.S. Federal Reserve started its monetary easing cycle with a large 50-basis-point rate cut MKTS/GLOB ** Indian pharma firms have a sizeable exposure to U.S. markets and earn a significant share of their rev from the geography ** Eighteen of the 21 index constituents are trading in green; top gainers Abbott India ABOT.NS and A
A
Reuters - 3周前

Indian shares set to open higher

INDIA STOCKS-Indian shares set to open higher BENGALURU, Sept 10 (Reuters) - Indian shares are set to open higher on Tuesday, tracking a rebound in global stocks ahead of the key U.S. inflation data and the Federal Reserve's interest rate decision. The GIFT Nifty GIFc1 was at 25,035 points, as of 08:06 a.m. IST, indicating the NSE Nifty 50 .NSEI will open above its previous close of 24,936.4. The benchmark Nifty 50 rose for the first time in four sessions on Monday, led by gains in consumer stoc
A
A
Reuters - 4周前

FDA Says Abbott Diabetes Care Inc Issues Recall For Certain Freestyle Libre 3 Sensors Due To Risk For Inaccurate High Glucose Readings

BRIEF-FDA Says Abbott Diabetes Care Inc Issues Recall For Certain Freestyle Libre 3 Sensors Due To Risk For Inaccurate High Glucose Readings Sept 5 (Reuters) - FDA: FDA: ABBOTT DIABETES CARE INC ISSUES RECALL FOR CERTAIN FREESTYLE LIBRE 3 SENSORS DUE TO RISK FOR INACCURATE HIGH GLUCOSE READINGS Further company coverage: ABT.N
A
Reuters - 4周前

Abbott U.S. Availability Of Lingo, Co's First Continuous Glucose Monitoring System Available Without Prescription

BRIEF-Abbott U.S. Availability Of Lingo, Co's First Continuous Glucose Monitoring System Available Without Prescription Abbott Laboratories ABT.N : ABBOTT: U.S. AVAILABILITY OF LINGO, CO'S FIRST CONTINUOUS GLUCOSE MONITORING SYSTEM AVAILABLE WITHOUT PRESCRIPTION ABBOTT: LINGO IS AVAILABLE IN THREE OPTIONS FOR $49, $89, AND $249 Source text for Eiko
A
Reuters - 4周前

Abbott follows rival Dexcom with OTC glucose monitor launch in US

UPDATE 3-Abbott follows rival Dexcom with OTC glucose monitor launch in US Adds details on the device in paragraph 3, background in paragraphs 6-7 By Sneha S K Sept 5 (Reuters) - Abbott ABT.N has launched its over-the-counter continuous glucose monitoring system in the U.S., the company said on Thursday, making it the second such device on the market to help people track their blood sugar levels.
A
Reuters - 4周前

Abbott launches over-the-counter continuous glucose monitor in the US

Abbott launches over-the-counter continuous glucose monitor in the US Sept 5 (Reuters) - Abbott ABT.N has launched its over-the-counter continuous glucose monitoring system Lingo in the United States, the company said on Thursday. Reporting by Sneha S K; Editing by Janane Venkatraman
A
Reuters - 4周前

Abbott Starts Study To Evaluate Use Of Deep Brain Stimulation System To Manage Severe Depression

BRIEF-Abbott Starts Study To Evaluate Use Of Deep Brain Stimulation System To Manage Severe Depression Sept 4 (Reuters) - Abbott Laboratories ABT.N : ABBOTT INITIATES CLINICAL STUDY TO EVALUATE THE USE OF ITS DEEP BRAIN STIMULATION SYSTEM TO MANAGE SEVERE DEPRESSION Source text for Eikon: ID:nPnbMNcLha Further company coverage: ABT.N
A

商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。

风险提示： 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明。